1. Home
  2. CNEY vs TCRT Comparison

CNEY vs TCRT Comparison

Compare CNEY & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CN Energy Group Inc.

CNEY

CN Energy Group Inc.

HOLD

Current Price

$0.85

Market Cap

5.9M

Sector

Industrials

ML Signal

HOLD

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

HOLD

Current Price

$1.97

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNEY
TCRT
Founded
2009
1998
Country
China
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9M
6.7M
IPO Year
2019
2025

Fundamental Metrics

Financial Performance
Metric
CNEY
TCRT
Price
$0.85
$1.97
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.8M
17.8K
Earning Date
02-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
24.66
EPS
N/A
N/A
Revenue
N/A
$15,900,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$1.67
52 Week High
$3.04
$5.48

Technical Indicators

Market Signals
Indicator
CNEY
TCRT
Relative Strength Index (RSI) 42.12 29.64
Support Level $0.53 N/A
Resistance Level $1.07 $2.97
Average True Range (ATR) 0.34 0.23
MACD -0.09 -0.07
Stochastic Oscillator 1.46 3.42

Price Performance

Historical Comparison
CNEY
TCRT

About CNEY CN Energy Group Inc.

CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.

Share on Social Networks: